tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
AVIR Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsAVIR Upcoming Earnings Report: What to Expect?
4M ago
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
Premium
The Fly
Atea announces results of Phase 2 study of bemnifosbuvir, ruzasvir
4M ago
Atea Pharmaceuticals to host hepatitis C virus KOL panel
Premium
The Fly
Atea Pharmaceuticals to host hepatitis C virus KOL panel
4M ago
Atea Pharmaceuticals appoints Howard Berman to board of directors
PremiumThe FlyAtea Pharmaceuticals appoints Howard Berman to board of directors
5M ago
Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
Premium
The Fly
Atea Pharmaceuticals price target lowered to $6 from $6.20 at Morgan Stanley
5M ago
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
Premium
The Fly
Atea Pharmaceuticals doses first patient in C-BEYOND, Phase 3 study
5M ago
Atea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts
PremiumCompany AnnouncementsAtea Pharmaceuticals Faces Challenges Amid Workforce Reductions and Cost-Cutting Efforts
6M ago
Atea Pharmaceuticals’ Promising Earnings Call Highlights
Premium
Company Announcements
Atea Pharmaceuticals’ Promising Earnings Call Highlights
6M ago
Atea Pharmaceuticals Advances HCV Program with FDA Approval
Premium
Company Announcements
Atea Pharmaceuticals Advances HCV Program with FDA Approval
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100